Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer : The OLI-P Phase 2 Clinical Trial
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved..
BACKGROUND: Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research.
OBJECTIVE: We hypothesize that aRT is safe and effective in gallium-68 prostate-specific membrane antigen targeted positron emission tomography (PSMA-PET)-staged oligometastatic PCa patients.
DESIGN, SETTING, AND PARTICIPANTS: A nonrandomized, prospective, investigator-initiated phase 2 trial recruited patients with oligometastatic PCa (five or fewer lymph node or osseous metastases) after local curative therapy, without significant comorbidity and androgen deprivation therapy (ADT), at two German centers from 2014 to 2018.
INTERVENTION: All PSMA-PET-positive metastases were treated with aRT. No systemic therapy was initiated.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was treatment-related toxicity (grade ≥2) 24 mo after aRT. A one-sided single-sample test of proportions was planned to test whether the endpoint occurs in <15% of the patients. Key secondary endpoints were time to progression of prostate-specific antigen (PSA) and time to ADT, which were associated with potential prognostic factors by Cox regression.
RESULTS AND LIMITATIONS: Of 72 patients, 63 received aRT (13% dropout rate). The median follow-up was 37.2 mo. No treatment-related grade ≥2 toxicity was observed 2 yr after treatment. The median time to PSA progression and time to ADT were 13.2 and 20.6 mo, respectively. Of the patients, 21.4% were free of PSA progression after 3 yr.
CONCLUSIONS: It was observed that aRT is safe, and midterm PSA progression and ADT-free time were achieved in one of five patients. Randomized clinical trials are indicated to further evaluate the option of delaying ADT in selected patients.
PATIENT SUMMARY: In this clinical trial, 63 patients with up to five metastases of prostate cancer without androgen deprivation therapy were included. We showed that local ablative radiotherapy is safe and that one in five patients had no recurrent prostate-specific antigen value after 3 yr. Local ablative radiotherapy might be an option to avoid systemic therapy in selected patients.
| Errataetall: |
CommentIn: Nat Rev Urol. 2022 May;19(5):259-260. - PMID 35075272 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
European urology oncology - 5(2022), 1 vom: 01. Feb., Seite 44-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hölscher, Tobias [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.05.2022 Date Revised 30.06.2022 published: Print-Electronic CommentIn: Nat Rev Urol. 2022 May;19(5):259-260. - PMID 35075272 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euo.2021.10.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333228804 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333228804 | ||
| 003 | DE-627 | ||
| 005 | 20231225221226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euo.2021.10.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333228804 | ||
| 035 | |a (NLM)34785189 | ||
| 035 | |a (PII)S2588-9311(21)00184-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hölscher, Tobias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer |b The OLI-P Phase 2 Clinical Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.05.2022 | ||
| 500 | |a Date Revised 30.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Rev Urol. 2022 May;19(5):259-260. - PMID 35075272 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research | ||
| 520 | |a OBJECTIVE: We hypothesize that aRT is safe and effective in gallium-68 prostate-specific membrane antigen targeted positron emission tomography (PSMA-PET)-staged oligometastatic PCa patients | ||
| 520 | |a DESIGN, SETTING, AND PARTICIPANTS: A nonrandomized, prospective, investigator-initiated phase 2 trial recruited patients with oligometastatic PCa (five or fewer lymph node or osseous metastases) after local curative therapy, without significant comorbidity and androgen deprivation therapy (ADT), at two German centers from 2014 to 2018 | ||
| 520 | |a INTERVENTION: All PSMA-PET-positive metastases were treated with aRT. No systemic therapy was initiated | ||
| 520 | |a OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was treatment-related toxicity (grade ≥2) 24 mo after aRT. A one-sided single-sample test of proportions was planned to test whether the endpoint occurs in <15% of the patients. Key secondary endpoints were time to progression of prostate-specific antigen (PSA) and time to ADT, which were associated with potential prognostic factors by Cox regression | ||
| 520 | |a RESULTS AND LIMITATIONS: Of 72 patients, 63 received aRT (13% dropout rate). The median follow-up was 37.2 mo. No treatment-related grade ≥2 toxicity was observed 2 yr after treatment. The median time to PSA progression and time to ADT were 13.2 and 20.6 mo, respectively. Of the patients, 21.4% were free of PSA progression after 3 yr | ||
| 520 | |a CONCLUSIONS: It was observed that aRT is safe, and midterm PSA progression and ADT-free time were achieved in one of five patients. Randomized clinical trials are indicated to further evaluate the option of delaying ADT in selected patients | ||
| 520 | |a PATIENT SUMMARY: In this clinical trial, 63 patients with up to five metastases of prostate cancer without androgen deprivation therapy were included. We showed that local ablative radiotherapy is safe and that one in five patients had no recurrent prostate-specific antigen value after 3 yr. Local ablative radiotherapy might be an option to avoid systemic therapy in selected patients | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Image guided, Radiosurgery | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Neoplasm metastasis | |
| 650 | 4 | |a Positron emission tomography | |
| 650 | 4 | |a Prospective studies | |
| 650 | 4 | |a Prostate-specific antigen | |
| 650 | 4 | |a Prostatic neoplasms | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Androgens |2 NLM | |
| 650 | 7 | |a Gallium Radioisotopes |2 NLM | |
| 650 | 7 | |a Gallium-68 |2 NLM | |
| 650 | 7 | |a 98B30EPP5S |2 NLM | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Baumann, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kotzerke, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Zöphel, Klaus |e verfasserin |4 aut | |
| 700 | 1 | |a Paulsen, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Arndt-Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Zips, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Koi, Lydia |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Löck, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Mechthild |e verfasserin |4 aut | |
| 700 | 1 | |a Wirth, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Lohaus, Fabian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European urology oncology |d 2018 |g 5(2022), 1 vom: 01. Feb., Seite 44-51 |w (DE-627)NLM285558595 |x 2588-9311 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2022 |g number:1 |g day:01 |g month:02 |g pages:44-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euo.2021.10.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2022 |e 1 |b 01 |c 02 |h 44-51 | ||